Level of toll-like receptor agonist exposure differentially determines chemokine production in humans

Author： Lissitsyn Yuriy   Becker Allan B.   Kozyrskyj Anita L.   HayGlass Kent T.  

Publisher： NRC Research Press

ISSN： 1205-7541

Source： Canadian Journal of Physiology and Pharmacology, Vol.85, Iss.7, 2007-07, pp. : 739-746

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers

By Tarhini Ahmad A   Kirkwood John M   Krieg Arthur M  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 5, 2009-05 ,pp. : 587-603

Informa Healthcare

Access to resources Recommend Favorite

Oxidised phospholipid regulation of Toll-like receptor signalling

By Erridge Clett   Spickett Corinne M  

Redox Report, Vol. 12, Iss. 1-2, 2007-02 ,pp. : 76-80

Maney Publishing

Access to resources Recommend Favorite

Antisense modulation of Toll-like receptor 4 expression

By  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 12, 2003-12 ,pp. : 1887-1889

Informa Healthcare

Access to resources Recommend Favorite

Toll-like receptor 9 agonists as cancer therapeutics

By Holtick Udo   Scheulen Max E   von Bergwelt-Baildon Michael S   Weihrauch Martin R  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 3, 2011-03 ,pp. : 361-372

Informa Healthcare

Access to resources Recommend Favorite

Toll-Like Receptor Agonists as Adjuvants for HIV Vaccines

By  

Current Medicinal Chemistry, Vol. 18, Iss. 33, 2011-11 ,pp. : 5079-5082

Bentham Science Publishers

Access to resources Recommend Favorite